SELLAS to Host Virtual Annual Meeting of Stockholders
May 22 2020 - 8:30AM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the
“Company”), a late-stage clinical biopharmaceutical company focused
on the development of novel cancer immunotherapies for a broad
range of cancer indications, today announced that it will hold its
2020 Annual Meeting of Stockholders (the “Annual Meeting”)
virtually due to the public health impact of the coronavirus
(COVID-19) pandemic and to prioritize the health and well-being of
meeting participants.
The Annual Meeting will be held in a
virtual-only format on Tuesday, June 9, 2020, at 8:30 a.m., Eastern
Time. The date and time of the Annual Meeting, as disclosed in the
previously distributed Notice of the Annual Meeting and Definitive
Proxy Statement (the "Notice and Proxy Statement"), has not
changed.
Stockholders of record and registered beneficial
owners as of the close of business on April 13, 2020 will be able
to vote and ask questions during the meeting through the online
platform. Online access to the Annual Meeting will begin at 8:15
a.m. Eastern Time. Stockholders will not be able to attend the
Annual Meeting in person.
SELLAS encourages stockholders to vote and
submit their proxies in advance of the Annual Meeting by one of the
methods described in the proxy materials for the Annual
Meeting.
Attending the Virtual Annual
Meeting
Stockholders of record as of April 13, 2020 can
attend the meeting by accessing
www.meetingcenter.io/257687071 and entering the 15-digit control
number found on their proxy card, voting instruction form, notice
of internet availability of proxy materials, or email previously
received. Stockholders may vote during the Annual Meeting by
following the instructions available on the meeting website during
the meeting.
Participating, Voting Electronically and
Submitting Questions at the Virtual Annual Meeting
Stockholders of Record
Stockholders of record will be able to
participate in the Annual Meeting, vote electronically and submit
questions during the live webcast of the meeting, without advance
registration. The two items of information needed to access the
live webcast of the meeting are the following:
The 15-digit control number found on the proxy
card, voting instruction form, notice of internet availability of
proxy materials, or email previously received
Meeting password: SLS2020
Beneficial Owners
Beneficial stockholders as of April 13, 2020 who
hold shares through an intermediary, such as a bank, broker or
nominee, and who want to attend the Annual Meeting, must register
in advance to participate in the Annual Meeting, vote
electronically and submit questions during the live webcast of the
meeting. To register in advance, beneficial stockholders must
obtain a legal proxy from the bank, broker or other nominee that
holds their shares giving them the right to vote the shares and
must forward a copy of the legal proxy along with their email
address to Computershare Trust Company, N.A. (“Computershare”).
Requests for registration should be directed to
Computershare by email at legalproxy@computershare.com no later
than 5:00 p.m. Eastern Time, on June 4, 2020. Stockholders will
receive a confirmation of their registration and instructions on
how to attend the meeting by email after Computershare receives
registration materials.
Questions
Stockholders may submit questions in advance of
the Annual Meeting by emailing the question, along with proof
of ownership, to questions2020@sellaslife.com prior to 8:30 a.m.
Eastern Time on June 8, 2020. Stockholders may also submit
questions during the Annual Meeting through the online platform in
accordance with the instructions above. The Company will, subject
to time constraints, answer all questions that are pertinent to the
business of the Annual Meeting and will give priority to questions
submitted in advance.
The proxy materials, including the proxy card
and Notice of Internet Availability of Proxy Materials, previously
distributed along with the Notice and Proxy Statement, will not be
updated to reflect the change in location and may continue to be
used to vote shares in connection with the Annual Meeting.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical
biopharmaceutical company focused on the development of novel
cancer immunotherapeutics for a broad range of cancer indications.
SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed
from Memorial Sloan Kettering Cancer Center and targets the Wilms
Tumor 1 (WT1) protein, which is present in an array of tumor types.
GPS has potential as a monotherapy or in combination to address a
broad spectrum of hematologic malignancies and solid tumor
indications. SELLAS’ second product candidate, nelipepimut-S (NPS),
is a HER2-directed cancer immunotherapy with potential for the
treatment of patients with early stage breast cancer with low to
intermediate HER2 expression, otherwise known as HER2 1+ or 2+,
which includes triple negative breast cancer patients, following
standard of care. For more information on SELLAS, please
visit www.sellaslifesciences.com.
Investor Contacts Adam Holdsworth PCG Advisory
646-862-4607 adamh@pcgadvisory.com SELLAS Life Sciences Group,
Inc.Investor Relations 917-438-4353 info@sellaslife.com
Source: SELLAS Life Sciences Group
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024